D
David M. Dorfman
Researcher at Brigham and Women's Hospital
Publications - 249
Citations - 13528
David M. Dorfman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Lymphoma & T cell. The author has an hindex of 58, co-authored 236 publications receiving 12356 citations. Previous affiliations of David M. Dorfman include Boston Children's Hospital & Boston Medical Center.
Papers
More filters
Journal ArticleDOI
Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production
Julia A. Brown,David M. Dorfman,Feng-Rong Ma,Elizabeth L. Sullivan,Oliver Munoz,Clive Wood,Edward A. Greenfield,Gordon J. Freeman +7 more
TL;DR: It is shown that blockade of PD-L2 on dendritic cells results in enhanced T cell proliferation and cytokine production, including that of IFN-γ and IL-10, which is consistent with the hypothesis that iDC have a balance of stimulatory vs inhibitory molecules that favors inhibition.
Journal ArticleDOI
TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells.
Norimoto Kobayashi,Piia Karisola,Victor Pena-Cruz,David M. Dorfman,Masahisa Jinushi,Sarah E. Umetsu,Manish J. Butte,Haruo Nagumo,Irene Chernova,Baogong Zhu,Arlene H. Sharpe,Susumu Ito,Glenn Dranoff,Gerardo G. Kaplan,José M. Casasnovas,Dale T. Umetsu,Rosemarie H. DeKruyff,Gordon J. Freeman +17 more
TL;DR: The results show that TIM-4 and TIM-1 are immunologically restricted members of the group of receptors whose recognition of PS is critical for the efficient clearance of apoptotic cells and prevention of autoimmunity.
Journal ArticleDOI
Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma
TL;DR: PD-1 is a useful new marker for angioimmunoblastic lymphoma and lends further support to a model of T-cell lymphomagenesis in which specific sub types of T cells may undergo neoplastic transformation and result in specific, distinct histologic, immunophenotypic, and clinical subtypes ofT-cell neoplasia.
Journal ArticleDOI
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma
Oreofe O. Odejide,Oliver Weigert,Oliver Weigert,Andrew A. Lane,Dan Toscano,Matthew A. Lunning,Nadja Kopp,Sunhee Kim,Diederik van Bodegom,Sudha Bolla,Jonathan H. Schatz,Jonathan H. Schatz,Julie Teruya-Feldstein,Ephraim P. Hochberg,Abner Louissaint,David M. Dorfman,Kristen E. Stevenson,Scott J. Rodig,Pier Paolo Piccaluga,Eric D. Jacobsen,Stefano Pileri,Nancy L. Harris,Simone Ferrero,Giorgio Inghirami,Steven M. Horwitz,David M. Weinstock +25 more
TL;DR: The mutational landscape of AITL is characterized by high frequencies of overlapping mutations in epigenetic modifiers and targetable mutations in a subset of cases.
Journal ArticleDOI
Highly efficient therapeutic gene editing of human hematopoietic stem cells.
Yuxuan Wu,Jing Zeng,Jing Zeng,Benjamin P. Roscoe,Pengpeng Liu,Qiuming Yao,Cicera R. Lazzarotto,M. Kendell Clement,Mitchel A. Cole,Mitchel A. Cole,Kevin Luk,Cristina Baricordi,Anne H. Shen,Anne H. Shen,Chunyan Ren,Chunyan Ren,Erica B. Esrick,Erica B. Esrick,John P. Manis,John P. Manis,David M. Dorfman,David M. Dorfman,David A. Williams,David A. Williams,Alessandra Biffi,Carlo Brugnara,Carlo Brugnara,Luca Biasco,Christian Brendel,Luca Pinello,Shengdar Q. Tsai,Scot A. Wolfe,Daniel E. Bauer,Daniel E. Bauer +33 more
TL;DR: Optimized conditions for ribonucleoprotein delivery of Cas9–sgRNA complexes enables precise and efficient gene editing to restore fetal hemoglobin expression in sickle cell disease patient-derived HSCs.